CRF1 Receptor Antagonists for CAH Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for congenital adrenal hyperplasia (CAH) often require high doses of glucocorticoids, leading to side effects such as iatrogenic Cushing's syndrome, cardiovascular risks, and bone mineral density issues, while failing to adequately suppress excessive ACTH and androgen production.
Innovation Solution
Development of compounds that act as CRF1 receptor antagonists, specifically those of Formula (I) or their pharmaceutically acceptable salts, to reduce ACTH levels and normalize androgen production, thereby allowing for lower physiologic doses of hydrocortisone and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-generated harmful factors
If high doses of glucocorticoids are used to suppress androgen excess in CAH patients, then androgen production is reduced, but side effects such as iatrogenic Cushing's syndrome, cardiovascular risks, and bone mineral density loss increase
Solution Approach 1:
The patent introduces CRF1 receptor antagonists as an intermediary substance that mediates the treatment of CAH by blocking the CRF1 receptor, thereby reducing ACTH secretion. This intermediary approach allows for the suppression of androgen excess without requiring high doses of glucocorticoids, thus avoiding the associated side effects while achieving the desired therapeutic effect.
Solution Approach 2:
The patent changes the therapeutic parameter from direct glucocorticoid replacement to CRF1 receptor blockade. By altering the mechanism of action from hormone replacement to receptor antagonism, the treatment achieves superior suppression of ACTH and androgen production while using lower, more physiologic doses of hydrocortisone, thereby reducing iatrogenic side effects.
2Reliability
If physiologic doses of hydrocortisone are used for cortisol replacement, then cortisol deficiency is addressed, but ACTH and androgen production remain uncontrolled
Solution Approach 1:
The patent merges two therapeutic approaches into a single treatment strategy: CRF1 receptor antagonism combined with physiologic dose hydrocortisone replacement. This combination allows simultaneous achievement of cortisol replacement and ACTH suppression, thereby controlling androgen production without the need for high-dose glucocorticoids.
Solution Approach 2:
The CRF1 receptor antagonist acts as an intermediary that enables the use of lower, more physiologic doses of hydrocortisone while still achieving adequate suppression of ACTH and androgen excess. The antagonist blocks the positive feedback loop that would otherwise require high-dose glucocorticoids for control.
3Object-generated harmful factors
If glucocorticoid doses are increased to treat androgen excess, then androgen production is suppressed, but glucose intolerance and decreased bone mineral density occur
Solution Approach 1:
The patent changes the therapeutic parameter from high-dose glucocorticoid therapy to CRF1 receptor antagonism combined with physiologic dose replacement. This parameter change achieves superior androgen suppression while maintaining glucose metabolism and bone health, as the lower hydrocortisone doses do not cause the metabolic side effects associated with high-dose therapy.
Data Source
AI summary
Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof.